(NASDAQ: ENVB) Enveric Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Enveric Biosciences's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ENVB's revenue for 2025 to be $72,940,050, with the lowest ENVB revenue forecast at $72,940,050, and the highest ENVB revenue forecast at $72,940,050. On average, 1 Wall Street analysts forecast ENVB's revenue for 2026 to be $72,940,050, with the lowest ENVB revenue forecast at $72,940,050, and the highest ENVB revenue forecast at $72,940,050.
In 2027, ENVB is forecast to generate $109,410,075 in revenue, with the lowest revenue forecast at $109,410,075 and the highest revenue forecast at $109,410,075.